Cell Therapy Market Size, Growth, Outlook 2023-2030 | DataM Intelligence

August 23 19:27 2023
Cell Therapy Market Size, Growth, Outlook 2023-2030 | DataM Intelligence
Cell Therapy Market – DataM Intelligence
Cell Therapy Market is estimated to grow at a CAGR of 16.3% during the forecast period 2023-2030

Market Overview:

The global cell therapy market is a vibrant and booming sector of the overall biotechnology industry. Cellular therapy (CT) involves the transplantation of human cells to replace or repair damaged tissue or cells. Several distinct kinds of cells can be utilized as an element of treatments or therapies for a number of diseases and disorders with the help of new technologies, inventive products, and infinite imagination. Furthermore, the most popular kind of cell therapy for treating a range of hematologic and blood cancers is hematopoietic stem cell transplantation, often known as a bone marrow transplant. 

Market Size Growth Rate:

According to the DataM market research report, the global cell therapy market size is valued at USD 8.4 billion in 2022, it is expected to reach USD 27.1 billion by 2030, with growth at a CAGR of 16.3% over the forecast period 2023-2030. North America is estimated to contribute 37.4% to the growth of the global market over the forecast period.

The global cell therapy market is driven by factors such as the high prevalence of chronic diseases, technological advancements, growing utilization of advanced delivery methods, the rising applications of cell therapy in several disorders, and expansion of utilization of stem cells for cell therapy. On the other hand, the high cost of the cell therapy, risk of complications and limitations associated with the stem cell therapy restrain market growth.


For More Insights about the Market Request Free Sample Here: https://www.datamintelligence.com/download-sample/cell-therapy-market


Market Drivers:

The growing number of people with chronic diseases such as cancer, neurological and cardiovascular diseases is propelling the global demand for cell therapy. For instance, according to statistics from the World Health Organization (WHO) for 2022, malignancies account for 9.3 million chronic illness fatalities annually, chronic respiratory diseases (4.1 million) and cardiovascular disorders (17.9 million).

The ability to self-renew and produce more stem cells as well as the aptitude to develop into distinct specialized cell type makes stem cells one of a kind in the bodies. The advantages of stem cells encompass a wide range of medicinal uses, from repairing damaged tissues, curing blood disorders, and battling neurological diseases to possibly reversing aging and resolving infertility. They continue to be the subject of intensive investigation due to their enormous potential to transform medicine and dramatically enhance human health.  

Market Restraints:

It is anticipated that the cell therapy market may hamper due to the high cost of stem cell therapy. The cost of stem cell therapy can be anywhere in between $5000-$50,000 in USD. Treatment cost can differ highly depending on several different factors. The private cord blood banking costs around $300 to $2,300 USD for processing after collection and then beginning storage, with supplementary annual storage charges after that. The cost for stem cell therapy can range in between $5000-$50,000 USD, with $25,000 USD average cost. 

Despite their success, CAR T-cell therapy still has significant drawbacks that need to be resolved. These drawbacks include the potentially fatal toxicities associated with CAR T-cell therapy including cytokine release syndrome, extended cytopenias and neurologic toxicities, inhibition and obstruction in B-cell malignancies, restricted persistence, antigen escape, immunosuppressive microenvironment, along with inadequate effectiveness against solid tumors. These factors may restrain the market’s growth.

Market Opportunities:

The development and expansion in the field of stem cell provide a significant potential opportunity for providers of cell therapy for treatment purpose. Cell treatments may be used to treat conditions such as infectious disease, cancer, autoimmune illness, urine issues, repair spinal cord injuries, and treat patients with neurological diseases. They may also be used to treat infectious disease and in joints rebuild the damaged cartilage. Companies can seize this opportunity by providing specialized solutions for these disorders. Such kind of therapies that are safe, cost-effective, and provide better treatments for untreatable diseases. 


View Full Report: https://www.datamintelligence.com/research-report/cell-therapy-market


COVID-19 Impact Analysis:

During the pandemic, the main topics of public health focus were COVID-19 prevention and transmission. The demand for cell therapies have been impacted by the reduction or redirection of awareness campaigns and efforts aimed at oncology and other chronic disease. As of 2023, the COVID-19 situation is recovering and all patients can access healthcare facilities which drive the demand for the cell therapy worldwide. As a new therapeutic and research approach for COVID-19, stem cell therapy or organoid models derived from stem cell are currently receiving a lot of interest.

Russia-Ukraine War Impact Analysis:

Due to the low prevalence as well as absence of major market participants in this region, it is predicted that the Russia-Ukraine conflict will not have a significant effect on the worldwide cell therapy market. The growth of the global cell therapy market, however, is anticipated to be relatively unaffected by the import and export of raw materials over the forecast period.

Recent Developments in the Industry:

  1. On June 1, 2023, Adaptimmune Therapeutics plc stated that it had successfully amalgamated with TCR2 Therapeutics Inc. in an all-stock transaction to form a leading provider of T-cell treatment for solid tumors. Engineered T-cell treatments that target MAGE-A4 and mesothelin, that are expressed on a variety of solid tumors, are used by Adaptimmune’s leading clinical franchises.  
  2. On May 18, 2023, A clinical-stage biotechnology company, Adicet Bio, Inc., focused on discovering and creating armored allogeneic gamma delta CAR (chimeric antigen receptor) “off-the-shelf” T cell therapy candidate aimed at CD70+ cancers, presented preclinical data emphasizing ADI-270 at the American Society of Gene & Cell Therapy’s, 26th Annual Meeting. In this research, gamma delta T cells engineered to express CD70 CAR were created and grew well without being visibly hampered by CD70-mediated fratricide.
  3. On February 24, 2022, Novel transfection kits, TransIT-VirusGEN SELECT were introduced by Mirus Bio, a top supplier of delivery systems within Gamma Biosciences, for the mass manufacture of viral vectors used in cell and gene therapy applications. The kits, which include the TransIT-VirusGEN Transfection enhancer, reagent, and complex formation solution, serve pre-clinical and process development operations. The complete kits are made to increase the plasmid DNA construct’s packaging and transfer to adherent and suspension HEK 293 cell types for adeno-associated virus (AAV) or lentivirus (LV) production.

Market Segmentation:

As per the research analysis, the global cell therapy market is segmented by delivery technology (non-viral delivery and viral delivery), by cell type (stem cell and non-stem cell), by therapy type (autologous therapy and allogeneic therapy) by application (cancer, autoimmune disorders, musculoskeletal disorders, dermatology and others), by end user (hospitals, specialty clinics, and others).

  1. Based on application, the cancer segment is estimated to contribute 36.3% to the growth of the global market over the forecast period (2023-2030). Cell Therapy is essential in cancer because of the growing positive outcomes and regulatory approvals by authorities for utilization of cell therapy for treatment of cancer. Cell therapy is mostly utilized for management of cancer and its type.
  2. Moreover, numerous centers are currently researching on stem cell therapy for cancer. Cell therapy makes use of the immune system’s innate capacity to locate and eradicate aberrant cells in the body when employed to treat cancer. The same sort of cancer treatment is known by a variety of names, such as adoptive cell therapy or immune cell therapy. Customized immune system cells can either be selectively obtained from a patient’s tumor and cultivated in large quantities in the laboratory before being infused back into the patient’s body by intravenous infusion, or they are modified to detect specific tags on an individual’s malignancy. 
  3. The Food and Drug Administration (FDA) has granted approval for six cell therapies to treat blood malignancies, while there are around 36 National Cancer Institute-Designated Extensive Cancer Centers with programs in cell therapy. With the rising prevalence of cancer and advances in cancer treatment, the demand for cell therapy in cancer treatment settings is expected to expand, resulting in better patient outcomes and treatment efficacy.

Geographical Classification:

The global cell therapy market is segmented into major countries, including North America, Europe, South America, Asia Pacific, and Middle East & Africa.

North America Cell Therapy Market:

The presence of huge number of key players settled in the region, technological advancements and high research activities along with developments of novel stem cell therapies such as CAR T-cell therapy by major players in the area makes it the highest market shareholder in cell therapy market. The demand for cell therapy in the pharmaceutical as well as biotechnology industry is driven by an increase in the amount of technologies and rising number of disorders among population in the region.

Asia-Pacific Cell Therapy Market:

Various novel advancements are taking place in the region including advancements in research. For instance, on December 22, 2022, Yescarta, a chimeric antigen receptor T-cell therapy, has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for the first-line therapy of patients having relapsed/refractory large B-cell lymphoma, including those with diffuse large B-cell lymphoma, transformed follicular lymphoma, primary mediastinal large B-cell lymphoma, and high-grade B-cell lymphoma. Moreover, the expanding partnerships and research studies in this region specifically product launch in Japan is fueling the growth. 

Europe Cell Therapy Market:

Pharmaceutical products/systems are governed by strict regulatory guidelines in Europe. Before being approved and released onto the market, therapy, medication and other systems must pass stringent safety and efficiency tests. High regulatory criteria are followed, which guarantees the quality of the treatment and increases consumer confidence. Also, the increasing chronic disorders and growing number of approvals drive the market in this region.

Competitive Analysis:

There are numerous international, regional, and local suppliers in the global cell therapy industry. The local market is rife with competition. Based on price, product quality, and dependability, the vendors compete. As a result, suppliers must offer items that are both affordable and efficient if they want to thrive and survive in a cutthroat market.

Major Companies:

Major companies working towards the market’s growth include Thermo Fisher Scientific Inc., Adaptimmune Therapeutics plc., Adicet Bio, Bio-Rad Laboratories, Inc., Cellectis, MaxCyte Inc, Mirus Bio LLC, BEX Co. Ltd, Celetrix, LLC, Harvard Bioscience Inc. (BTX) and others.  

Related Reports

Additional Benefits Post Purchase:

1) Unlimited Analyst support for a period of 1 year. 

2) Any query with regard to the scope offered will be addressed within 24- 48 hours.

3) An Excel sheet with market numbers will be provided separately.

The Full Report has the below insights: 

  • The report offers a comprehensive evaluation of the market in terms of market value (US) and Y-o-Y Growth Rates (%). It does so via in-depth qualitative insights, historical data (2021-2022), and verifiable projections about market size during the forecast period (2023-2030).
  • Visualize the composition of the global cell therapy market segmentation by delivery technology, cell type, therapy type, application, end user, and region, highlighting the key commercial assets and players. 
    • By Delivery Technology: Non-Viral Delivery (Physical Methods [Electroporation {Reversible electroporation, Irreversible electroporation}, Needle Injection, Sono-poration, Others], Chemical Methods [Liposome-based, Polymer-based]), Viral Delivery (DNA-based Viral Vectors, RNA-based Viral Vectors, Oncolytic-based Viral Vectors).
    • By Cell Type: Stem Cell, Non-Stem Cell.  
    • By Therapy Type: Autologous Therapy, Allogeneic Therapy.  
    • By Application: Cancer, Autoimmune Disorders, Musculoskeletal Disorders, Dermatology and Others.  
    • By End User: Hospitals, Specialty Clinics, and Others. 
    • By Region: North America, South America, Europe, Asia Pacific, Middle East & Africa.
  • Identify commercial opportunities in the global cell therapy market by analyzing trends and co-development deals.
  • The report also covers data insights on various industry forces such as porter’s five forces analysis, supply chain analysis, pricing analysis, and regulatory analysis.
  • Excel data sheet with thousands of data points of global cell therapy market-level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study. 
  • Product mapping in Excel for the key product of all major market players
  • The report will provide access to approximately 61 market data Non-Viral Delivery, 64 figures, and close to 180 pages. 

DMI Opinion:

The rising strategic initiatives by the key players shows the rising demand of cell therapy for treatment of several diseases including cancer, dermatological conditions, neurological disorders and more. Numerous players are currently working on different cell types and delivery technologies. Positive outcomes of the utilization of cell therapy also show that the market of cell therapy will blossom in upcoming years owing to the high demand of cell therapy for treatment purpose.

About Us:

DataM Intelligence 4Market Research is a market intelligence platform that gives access to syndicated, customized reports and consulting to its clients in one place. As a firm with rich experience in research and consulting across multiple domains, we are a one-stop solution that will cater to the needs of clients in key business areas. DataM Intelligence has an online platform whose coverage includes industries such as chemicals and materials, agriculture, health care services, animal feed, and food & beverages among others. Our platform has Insights on markets that uncover the latest market research data that are distinct from the competition. With coverage across 10 major industries in the marketplace research, DataM Intelligence benefits thousands of companies by helping them take their innovations early to the market by providing a complete view of the market with statistical forecasts. Our strategy centric framework and value-added services will let individuals and corporates with ease of access and custom personalization to research and markets.

Media Contact
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Send Email
Phone: 08774414866
Address:DATAM INTELLIGENCE 4MARKET RESEARCH LLP Ground floor, DSL Abacus IT Park, Industrial Development Area, Uppal, Hyderabad, Telangana 500039
State: Telangana
Country: India
Website: https://www.datamintelligence.com/research-report/cell-therapy-market